In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bridging the Hot Economics of Monoclonals and Genomics

Executive Summary

Abgenix's recent deals with Human Genome Sciences and CuraGen bridge two of the hottest biotechnology markets--monoclonal antibodies and genomics. The deals are structured slightly differently, but both accomplish the same thing: the use of each other's technological asset to create proprietary programs.
Advertisement

Related Content

The State of Investing in Antibody Technology

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

IV001299

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel